Abstract
Candesartan cilexetil is an angiotensin II receptor antagonist, and candesartan, its active metabolite, is metabolized by CYP2C9. However, the effect of CYP2C9*3 on candesartan metabolism is not established. We characterized the kinetics of candesartan by CYP2C9*1/*1 and CYP2C9*1/*3 in human liver microsomes. The difference between the two was not significant. Subsequently, CYP2C9*1 and CYP2C9*3 (Leu359) were expressed in yeast, and the kinetics of candesartan were determined. The wild-type showed the lower Km (345 vs 439 microM; 3/4) and higher Vmax/Km (1/3) than the Leu359 variant. Also, we investigated potential interaction between candesartan and warfarin with both the wild-type and the Leu359 variant. Candesartan had no effect on S-warfarin 7-hydroxylation. In contrast, S-warfarin inhibited candesartan metabolism by the wild-type (K = 17microM) greater than by the Leu359 variant (Ki = 36 microM). These findings suggest that CYP2C9*3 may change not only the metabolic activity but also the inhibitory susceptibility compared with CYP2C9*1.
References
Feb 1, 1986·DNA·H MurakamiH Ohkawa
Feb 1, 1995·Pharmacogenetics·S L WangJ J Tsai
Sep 15, 1996·Archives of Biochemistry and Biophysics·R L HainingA E Rettie
Aug 1, 1996·Pharmacogenetics·T H Sullivan-KloseJ A Goldstein
Feb 23, 1996·Journal of Chromatography. B, Biomedical Applications·T MiyabayashiT Yashiki
Oct 23, 1997·Clinical Pharmacology and Therapeutics·A OdaniK Inui
Nov 14, 1997·Pharmacogenetics·D J StewardA E Rettie
Nov 14, 1997·Pharmacogenetics·K NasuT Ishizaki
Jan 22, 1998·Archives of Biochemistry and Biophysics·J WanY Funae
Jul 15, 1998·British Journal of Clinical Pharmacology·J O Miners, D J Birkett
Aug 11, 1998·Biochemical Pharmacology·H YamazakiT Shimada
Nov 24, 1998·Pharmacogenetics·H TakahashiH Echizen
Nov 26, 1998·Drugs·K J McClellan, K L Goa
Apr 7, 1999·European Journal of Clinical Pharmacology·A HemeryckF M Belpaire
Apr 20, 1999·Pharmacogenetics·R S KiddJ T Dalton
Apr 13, 2000·Pharmacogenetics·K TakanashiK Chiba
May 10, 2000·Pharmacogenetics·J O MinersJ A Goldstein
Jul 6, 2000·European Journal of Clinical Pharmacology·P TaavitsainenO Pelkonen
Citations
Nov 2, 2011·Drug Metabolism and Pharmacokinetics·Masahiro Hiratsuka
Jun 12, 2013·The Pharmacogenomics Journal·Y NiinumaM Hiratsuka
Sep 1, 2009·Toxicology·Shu-Feng ZhouMin Huang
Dec 20, 2013·HIV Medicine·K GedelaM Boffito
Dec 20, 2007·American Journal of Hypertension·Vincent J CanzanelloArlene B Chapman
Mar 21, 2007·Chemistry & Biodiversity·Bernard Testa, Stefanie D Krämer
Nov 3, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Teresa CabaleiroFrancisco Abad-Santos
Aug 26, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Duan LiuChao Chen
Mar 15, 2013·Pharmacological Reviews·Martin C MichelLisheng Liu
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Dec 1, 2004·Personalized Medicine·Julia KirchheinerJürgen Brockmöller
Apr 10, 2020·Clinical and Translational Science·Saaket AgrawalAlfred L George
Dec 14, 2004·Cardiovascular Drug Reviews·Christoph H GleiterKlaus Mörike
Sep 1, 2006·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Toshiro NiwaAkira Takagi
May 30, 2003·Journal of Medicinal Chemistry·Boris Schmidt, Bernhard Schieffer
Nov 25, 2021·Archives of Pharmacal Research·Eui Hyun JungSeok-Yong Lee